Needham & Company Raises Aegerion Pharmaceuticals (AEGR) Price Target to $30
Tweet
Share
E-mailGet Alerts AEGR Hot Sheet
Price: $1.97 --0%
Rating Summary:
8 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 1 | Down: 5 | New: 5
Rating Summary:
8 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 1 | Down: 5 | New: 5
Join SI Premium – FREE
Needham & Company boosted its price target on Buy-rated Aegerion Pharmaceuticals (NASDAQ: AEGR) from $22 to $30 after an FDA panel backed Lomitapide.
"Yesterday, an FDA Advisory Committee voted 13-2 in favor of approving lomitapide in patients with homozygous familial hypercholesterolemia (HoFH). While the panel did engage in a vigorous debate about the relative cost:benefit of lomitapide, most committee members came to the view that the benefits of significant LDL lowering in this patient population who are likely to die young of cardiovascular disease outweigh the less certain potential for liver toxicity. We view this as a clear de-risking event for Aegerion."
For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.
Shares of Aegerion Pharmaceuticals closed at $19.15 yesterday.
"Yesterday, an FDA Advisory Committee voted 13-2 in favor of approving lomitapide in patients with homozygous familial hypercholesterolemia (HoFH). While the panel did engage in a vigorous debate about the relative cost:benefit of lomitapide, most committee members came to the view that the benefits of significant LDL lowering in this patient population who are likely to die young of cardiovascular disease outweigh the less certain potential for liver toxicity. We view this as a clear de-risking event for Aegerion."
For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.
Shares of Aegerion Pharmaceuticals closed at $19.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walker & Dunlop (WD) PT Lowered to $55 at Citizens Amid Interest Rate Headwinds
- UBS Downgrades Scor SE (SCR:FP) (SCRYY) to Sell
- Snowflake Inc. (SNOW) PT Raised to $408 at Citizens on Positive Checks
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
